Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, took place on the 6–8 October. BOPA 2017 showcased the latest developments in oncology pharmacy.

Highlights from this year’s conference include talks on novel diagnostic methods and therapies for non-small cell lung cancer, refinements in precision medicine for prostate cancer, and clinical updates on pancreatic cancer with regards to the roles of both the clinician and the pharmacist.

BOPA 2017

06–08 October 2017 | Virtual Meeting

BOPA 2017

06–08 October 2017 | Virtual Meeting

The British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK, took place on the 6–8 October. BOPA 2017 showcased the latest developments in oncology pharmacy.

Highlights from this year’s conference include talks on novel diagnostic methods and therapies for non-small cell lung cancer, refinements in precision medicine for prostate cancer, and clinical updates on pancreatic cancer with regards to the roles of both the clinician and the pharmacist.

Targeted medicine for ALK-mutated NSCLC 2:48
Targeted medicine for ALK-mutated NSCLC
Yvonne Summers • 6 Oct 2017
The changing landscape of NSCLC diagnosis, monitoring and treatment 4:28
The changing landscape of NSCLC diagnosis, monitoring and treatment
Yvonne Summers • 6 Oct 2017
Key messages on prostate cancer treatment from BOPA 2017 0:34
Key messages on prostate cancer treatment from BOPA 2017
Robert Jones • 6 Oct 2017
Prostate cancer precision medicine 1:11
Prostate cancer precision medicine
Robert Jones • 6 Oct 2017
The role of pharmacists in utilizing novel pancreatic cancer treatments 1:49
The role of pharmacists in utilizing novel pancreatic cancer treatments
Islam Elkonaissi • 6 Oct 2017
Exciting advances in systemic therapy for prostate cancer: docetaxel and abiraterone 5:16
Exciting advances in systemic therapy for prostate cancer: docetaxel and abiraterone
Robert Jones • 6 Oct 2017
Digital disease tracking: the uMotif app for symptom-tracking 1:23
Digital disease tracking: the uMotif app for symptom-tracking
Nina Paton • 6 Oct 2017
Promising results from the uMotif app for CRC 1:46
Promising results from the uMotif app for CRC
Nina Paton • 6 Oct 2017
Multidisciplinary cancer research: overcoming the odds 1:58
Multidisciplinary cancer research: overcoming the odds
Islam Elkonaissi • 6 Oct 2017
Clinical update: lung and pancreatic cancer 1:55
Clinical update: lung and pancreatic cancer
Islam Elkonaissi • 6 Oct 2017
The role of pharmacists in the adoption of novel cancer immunotherapies 2:48
The role of pharmacists in the adoption of novel cancer immunotherapies
Yvonne Summers • 6 Oct 2017
The impact of novel NSCLC immunotherapies 3:26
The impact of novel NSCLC immunotherapies
Yvonne Summers • 6 Oct 2017
Upcoming pancreatic cancer study: PRIMUS001 1:35
Upcoming pancreatic cancer study: PRIMUS001
Derek Grose • 6 Oct 2017
Pancreatic cancer: The next 10 years 1:32
Pancreatic cancer: The next 10 years
Derek Grose • 6 Oct 2017
The PRECISION-Panc project: Speeding up scientific discovery to improve pancreatic cancer survival 3:01
The PRECISION-Panc project: Speeding up scientific discovery to improve pancreatic cancer survival
Derek Grose • 6 Oct 2017
The current treatment landscape for pancreatic cancer 2:03
The current treatment landscape for pancreatic cancer
Derek Grose • 6 Oct 2017
The content of VJOncology is intended for healthcare professionals